DNMT1 and neoplasm: Another emerging agent, CM-272, is a dual inhibitor targeting DNMT1 and G9a, offering a synergistic epigenetic blockade and demonstrating robust anti-tumor activity in hematologic malignancies and immune-responsive solid tumors [30].